Dova Pharmaceuticals, Inc.

17 articles with Dova Pharmaceuticals, Inc.

• Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

  9/27/2018

  Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease Patients Scheduled to Undergo a Procedure

• 

  FDA Approves Shionogi’s Mulpleta

  8/1/2018

  Shionogi, based in Osaka, Japan and Florham Park, New Jersey, announced that the U.S. Food and Drug Administration (FDA) approved Mulpleta (lusutrombopag) for thrombocytopenia in adults with chronic liver disease who were about to have a medical procedure performed.
• 

  Approved! FDA gives Dova Pharma’s Doptelet a Thumbs Up

  5/22/2018

  Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
• 

  Three Companies with FDA Decisions in the Next Week

  5/15/2018

  There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.

• Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018

  2/13/2018

  To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7796295 five to 10 minutes before the start of the call.

• Dova Pharmaceuticals Announces the Appointment of Mark W. Hahn as CFO

  1/30/2018

  Mark will officially commence in his role as Chief Financial Officer of Dova on January 31st, 2018.

• Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag NDA With Priority Review

  11/28/2017

  The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is May 21, 2018.

• Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results

  11/10/2017

  Dova reported a net loss of $9.7 million for the third quarter of 2017, compared to a net loss of $7.2 million for the same period in 2016.

• Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017

  11/3/2017

  A question-and-answer session will follow Dova's remarks.

• Dova Pharma To Present Phase III Avatrombopag Data At The 2017 Liver Meeting Of The American Association For The Study Of Liver Diseases (AASLD)

  10/11/2017

• Dova Pharma Announces New Drug Application Submission To FDA For Avatrombopag, A Second Generation Thrombopoietin Receptor Agonist

  9/22/2017

• Dova Pharma Reports Second Quarter 2017 Operating and Financial Results

  8/11/2017

• Dova Pharma To Announce Second Quarter 2017 Financial Results on August 10, 2017

  8/4/2017

• Dova Pharma Targets A 9-Figure Opportunity, But Should You Buy Its IPO?

  6/30/2017

• Dova Pharma To Ring The Nasdaq Stock Market Opening Bell In Celebration Of Its IPO

  6/29/2017

• Dova Pharma Announces Pricing Of Initial Public Offering

  6/29/2017

• Dova Pharma Announces Hiring Of CEO And Presentation At The 35th Annual J.P. Morgan Healthcare Conference

  1/6/2017